Multicenter Clinical Comparison of the 10 Minute AMDI Fast PCR Mini Respiratory Panel and the Cepheid Xpert Xpress CoV-2/Flu/RSV plus
Srinivasan, A.; Martin, R.; Allen, G.; Price, C.; Miller, D.; Mittal, S.; Ledo, C.; Alvarado, E.; Arroyo, Y.; Foltz, F.; Halle, P.; Hambalek, J. A.; Abebe, A.; Liu, Y.; Sun, A.; Janwari, H.; Allen, K.; Lu, H.-W.; Gutierrez, N.; Nako, J.; Martinez, B.; Walsh, P.; Johnsen, N.; Ross, C.; Casarez, N.; Fiore, A.; Perez, L.; Wright, D.; Babikian, S.; McDonald, J.; Kido, H.; Kuriyama, S.; Davis, R.; Heeren, T.; Miller, B.; Gill, F.; Okrongly, D.; Peytavi, R.
Show abstract
RT-PCR is the gold standard to determine the etiology of respiratory viral infections caused by SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus. Multiplex testing panels can test for infections or co-infections with these viruses at the point of care. Treatment using antiviral drugs and/or monoclonal antibodies and public health measures using vaccines and specific infection prevention practices depend upon accurate diagnoses. The AMDI Fast PCR Mini Respiratory Panel is a 10-minute RT-PCR test for use at the point of care to detect these viruses from a single anterior nasal swab. It is run on the Fast PCR Instrument with integrated cloud connectivity for data management. The clinical performance of the Fast PCR Mini Respiratory Panel test was established in a multi-center clinical study of 1906 participants using the Cepheid Xpert Xpress CoV-2/Flu/RSV plus test as the comparator. The study population included 242 Flu A, 77 Flu B, 71 RSV, and 87 SC2 positive samples and had an overall percent agreement of 97.2% (CI 96.4-97.9%), 99.7% (CI 99.4-99.9%), 99.3% (CI 98.8-99.6%) and 99.3% (CI 98.8-99.6%), respectively. Out of the total 85 (4.4%) discrepant results, 61 (72%) were associated with a low viral load. The AMDI Fast PCR Mini Respiratory Panel has excellent clinical performance, providing clinically useful information at the point of care in less than 10 minutes.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with centralized assays across healthcare facilities in the United States 97%
- Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution 96%
- Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges 96%
Similar papers in this journal
- Clinical evaluation of BD Veritor™ SARS-CoV-2 and Flu A+B Assay for point-of-care (POC) System 96%
- Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing 96%
- Real-time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with Variants of Concern 96%
Similar papers in this journal
- Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2 97%
- Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ System 96%
- SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing 95%
Similar papers in this journal
- Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness 96%
- Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type. 95%
- Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings 95%
Similar papers in this journal
- Clinical impact of the rapid molecular detection of RSV and influenza A and B virus in the emergency room 97%
- Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): a point-of-care PCR test for rapid detection of SARS-CoV-2 infection 96%
- Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.